Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes.

Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes.
复制标题

DOI:
10.1002/hed.26384
复制
发表时间:
2020-11
期刊:
Head & neck
影响因子:
--
通讯作者:
Phan J
Phan J
中科院分区:
其他
文献类型:
--
作者:
Bagley AF;Garden AS;Reddy JP;Moreno AC;Frank SJ;Rosenthal DI;Morrison WH;Gunn GB;Fuller CD;Shah SJ;Ferrarotto R;Sturgis EM;Gross ND;Phan J

文献摘要

参考文献

被引文献

相似文献

头颈部癌的再照射与局部失败率高和潜在的严重治疗相关毒性有关。我们报告我们的机构经验,再照射使用现代高度适形放射治疗方法的患者先前口咽部辐射。我们回顾了1999年至2019年在我们机构接受调强放射治疗(IMRT)、立体定向体部放射治疗(SBRT)和质子束放射治疗(PBT)的治愈性再照射的患者。疾病控制,生存率和再照射后的毒性率进行了测定。69名患者接受了评估。再照射后2年的局部控制率、无进展生存率和总生存率分别为77%、35%和51%。46%的患者发生了3级或更高(G3+)的晚期毒性,41%的患者在再照射期间或之后需要放置饲管。在选择口咽部放疗的患者中,高度适形再照射提供了可接受的局部控制,但G3+毒性和场外失败率仍然很高。这些发现证明需要继续评价新的多模态方法以改善肿瘤学结局。
Reirradiation of head and neck cancer is associated with high rates of locoregional failure and potentially severe treatment-related toxicity. We report our institutional experience of reirradiation using modern highly-conformal radiotherapy approaches in patients with prior oropharyngeal radiation. We reviewed patients receiving curative-intent reirradiation with intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton beam radiotherapy (PBT) at our institution from 1999 – 2019. Disease control, survival, and toxicity rates following reirradiation were determined. Sixty-nine patients were evaluated. Local control, progression-free survival, and overall survival at 2-years following reirradiation were 77%, 35%, and 51%, respectively. Grade 3 or greater (G3+) late toxicities occurred in 46% of patients and 41% required feeding tube placement during or after reirradiation. In select patients with prior oropharyngeal radiation, highly-conformal reirradiation offers acceptable local control, but G3+ toxicity and out-of-field failure rates remain high. These findings warrant continued evaluation of new multimodality approaches to improve oncologic outcomes.
DOI: 10.1016/j.ijrobp.2008.04.021
发表时间: 2009-02-01
影响因子: 7
作者:
Sulman, Erik P.;Schwartz, David L.;Garden, Adam S.
通讯作者: Garden, Adam S.
DOI: 10.1002/hed.24872
发表时间: 2017-10-01
影响因子: 2.9
作者:
Pollard, Courtney, III;Nguyen, Theresa P.;Phan, Jack
通讯作者: Phan, Jack
DOI: 10.1002/hed.20446
发表时间: 2006-11-01
影响因子: 2.9
作者:
Rosenthal, David I.;Asper, Joshua A.;Ang, K. Kian
通讯作者: Ang, K. Kian
DOI: 10.1120/jacmp.v17i3.6038
发表时间: 2016-05-08
影响因子: 2.1
作者:
Wang H;Wang C;Tung S;Dimmitt AW;Wong PF;Edson MA;Garden AS;Rosenthal DI;Fuller CD;Gunn GB;Takiar V;Wang XA;Luo D;Yang JN;Wong J;Phan J
通讯作者: Phan J
DOI: 10.1016/j.ijrobp.2016.11.019
发表时间: 2017-07-01
影响因子: 7
作者:
Cardenas, Carlos E.;Mohamed, Abdallah S. R.;Rosenthal, David I.
通讯作者: Rosenthal, David I.